iBio Posts $33M FY2026 Net Loss; Cash Runway Extends to FY2028
IBIO sits 86% above its 52-week low of $0.76.
Summary
iBio reported a $33.0 million net loss for fiscal 2026, up from $18.4 million, as R&D spending surged to advance its obesity pipeline. The company holds $88.0 million in cash and investments, extending its runway into fiscal 2028.
Key Events · Earnings and Guidance · IBIO
-
FY2026 Net Loss Widens to $33.0M
Net loss of $33.0 million for fiscal 2026, up from $18.4 million in fiscal 2025, driven primarily by an $11.3 million increase in R&D expenses to $19.6 million.
-
Cash Runway Extended to FY2028
Cash, cash equivalents, and investments in debt securities totaled $88.0 million as of June 30, 2026, which management states extends the cash runway into fiscal year 2028.
-
R&D Spending Surges on Pipeline Advancement
R&D expenses rose to $19.6 million from $8.3 million, including $8.4 million on consultants and outside services for IBIO-610 and IBIO-600 programs and a $2.5 million development milestone.
-
$5.0M Impairment of IBIO-101 Intangible Asset
The company recorded a $5.0 million impairment of its indefinite-lived intangible asset IBIO-101 during fiscal 2026; no such impairment was recorded in fiscal 2025.
Analysis · IBIO · Life Sciences
Fiscal 2026 results show a net loss of $33.0 million, nearly double the prior year's $18.4 million, driven by an $11.3 million increase in R&D spending as the company advanced its obesity and cardiometabolic pipeline into clinical development. The company ended the year with $88.0 million in cash and investments, which management says extends its runway into fiscal year 2028. The balance sheet also reflects the impact of two major financings completed during the year — an August 2025 public offering and a January 2026 private placement — which increased weighted-average shares outstanding from 10.5 million to 104.1 million, a roughly tenfold increase that explains the sharp drop in loss per share from $1.75 to $0.32 despite the larger absolute loss.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBIO was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.5M. The 52-week trading range was $0.76 to $3.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.